121 related articles for article (PubMed ID: 10631636)
1. Assessing multiple sclerosis activity: is the in vitro production of tumor necrosis factor-alpha, interleukins 2, 6, 4, and 10, and immunoglobulin G of value?
Schluep M; van Melle G; Henry H; Städler C; Roth-Wicky B; Magistretti PJ
J Neurol; 1999 Nov; 246(11):1041-50. PubMed ID: 10631636
[TBL] [Abstract][Full Text] [Related]
2. In vitro cytokine profiles as indicators of relapse activity and clinical course in multiple sclerosis.
Schluep M; van Melle G; Henry H; Städler C; Roth-Wicky B; Magistretti PJ
Mult Scler; 1998 Jun; 4(3):198-202. PubMed ID: 9762674
[TBL] [Abstract][Full Text] [Related]
3. Effects of interferon beta, cyclophosphamide and azathioprine on cytokine profile in patients with multiple sclerosis.
Totaro R; Passacantando A; Russo T; Parzanese I; Rascente M; Marini C; Tonietti G; Carolei A
Int J Immunopathol Pharmacol; 2005; 18(2):377-83. PubMed ID: 15888259
[TBL] [Abstract][Full Text] [Related]
4. Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis.
Weber F; Polak T; Günther A; Kubuschok B; Janovskaja J; Bitsch A; Poser S; Rieckmann P
Ann Neurol; 1998 Jul; 44(1):27-34. PubMed ID: 9667590
[TBL] [Abstract][Full Text] [Related]
5. Short-term treatment of relapsing remitting multiple sclerosis patients with interferon (IFN)-beta1B transiently increases the blood levels of interleukin (IL)-6, IL-10 and IFN-gamma without significantly modifying those of IL-1beta, IL-2, IL-4 and tumour necrosis factor-alpha.
Nicoletti F; Di Marco R; Patti F; Zaccone P; L'Episcopo MR; Reggio E; Xiang M; Nicoletti A; Reggio A
Cytokine; 2000 Jun; 12(6):682-7. PubMed ID: 10843745
[TBL] [Abstract][Full Text] [Related]
6. [T-cell interferon-gamma, tumor necrosis factor-alpha and interleukin-6 receptor binding in patients with multiple sclerosis. Effects of interferon-beta-1b treatment].
Bongioanni P; Romano MR; Boccardi B; Lombardo F; Moscato G; Mosti S; Baldini C; Nuti S; Meucci G; Rossi B
Rev Neurol; 1999 Nov 16-30; 29(10):893-9. PubMed ID: 10637835
[TBL] [Abstract][Full Text] [Related]
7. Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort.
Kalincik T; Horakova D; Dolezal O; Krasensky J; Vaneckova M; Seidl Z; Havrdova E
Clin Neurol Neurosurg; 2012 Sep; 114(7):940-6. PubMed ID: 22402204
[TBL] [Abstract][Full Text] [Related]
8. Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis.
Brod SA; Marshall GD; Henninger EM; Sriram S; Khan M; Wolinsky JS
Neurology; 1996 Jun; 46(6):1633-8. PubMed ID: 8649562
[TBL] [Abstract][Full Text] [Related]
9. Azathioprine and interferon beta(1a) in relapsing-remitting multiple sclerosis patients: increasing efficacy of combined treatment.
Lus G; Romano F; Scuotto A; Accardo C; Cotrufo R
Eur Neurol; 2004; 51(1):15-20. PubMed ID: 14631124
[TBL] [Abstract][Full Text] [Related]
10. [Therapeutic potential of interferon beta-1b and related drugs in multiple sclerosis: comparative meta-analysis].
Cendrowski W
Neurol Neurochir Pol; 2001; 35(4 Suppl):125-38. PubMed ID: 11873611
[TBL] [Abstract][Full Text] [Related]
11. IFN-beta 1b treatment of relapsing multiple sclerosis has no effect on CD3-induced inflammatory or counterregulatory anti-inflammatory cytokine secretion ex vivo after nine months.
Brod SA; Nelson LD; Khan M; Wolinsky JS
Int J Neurosci; 1997 Jun; 90(1-2):135-44. PubMed ID: 9285295
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.
Rudick RA; Cookfair DL; Simonian NA; Ransohoff RM; Richert JR; Jacobs LD; Herndon RM; Salazar AM; Fischer JS; Granger CV; Goodkin DE; Simon JH; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munchsauer FE; O'Reilly K; Priore RL; Whitham RH
J Neuroimmunol; 1999 Jan; 93(1-2):8-14. PubMed ID: 10378864
[TBL] [Abstract][Full Text] [Related]
13. The immunomodulatory properties of in vitro immunoglobulins are dose-dependent.
Reske D; Schoppe S; Broicher C; Petereit HF
Acta Neurol Scand; 2003 Oct; 108(4):267-73. PubMed ID: 12956861
[TBL] [Abstract][Full Text] [Related]
14. Hypothalamic-pituitary-adrenal axis function and cytokine production in multiple sclerosis with or without interferon-beta treatment.
Limone P; Ferrero B; Calvelli P; Del Rizzo P; Rota E; Berardi C; Barberis AM; Isaia GC; Durelli L
Acta Neurol Scand; 2002 May; 105(5):372-7. PubMed ID: 11982488
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-1 receptor antagonist, soluble tumor necrosis factor-alpha receptor type I and II, and soluble E-selectin serum levels in multiple sclerosis patients receiving weekly intramuscular injections of interferon-beta1a.
Perini P; Tiberio M; Sivieri S; Facchinetti A; Biasi G; Gallo P
Eur Cytokine Netw; 2000 Mar; 11(1):81-6. PubMed ID: 10705303
[TBL] [Abstract][Full Text] [Related]
16. Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-alpha)- and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-beta) treatment.
Ozenci V; Kouwenhoven M; Huang YM; Kivisäkk P; Link H
Clin Exp Immunol; 2000 Apr; 120(1):147-53. PubMed ID: 10759776
[TBL] [Abstract][Full Text] [Related]
17. Decreases in T-cell tumor necrosis factor alpha binding with interferon beta treatment in patients with multiple sclerosis.
Bongioanni P; Mosti S; Moscato G; Lombardo F; Manildo C; Meucci G
Arch Neurol; 1999 Jan; 56(1):71-8. PubMed ID: 9923763
[TBL] [Abstract][Full Text] [Related]
18. Interferon beta-1a induces tumor necrosis factor receptor 1 but decreases tumor necrosis factor receptor 2 leukocyte mRNA levels in relapsing-remitting multiple sclerosis.
Reuss R; Pohle S; Retzlaff K; Hemberger J; Oschmann P
Neuroimmunomodulation; 2009; 16(3):171-6. PubMed ID: 19246939
[TBL] [Abstract][Full Text] [Related]
19. The effects of interferon-beta on interleukin-10 in multiple sclerosis patients.
Ersoy E; Kuş CN; Sener U; Coker I; Zorlu Y
Eur J Neurol; 2005 Mar; 12(3):208-11. PubMed ID: 15693810
[TBL] [Abstract][Full Text] [Related]
20. Azathioprine reduces intrathecal IgG synthesis in multiple sclerosis.
Caputo D; Zaffaroni M; Ghezzi A; Cazzullo CL
Acta Neurol Scand; 1987 Feb; 75(2):84-6. PubMed ID: 3577680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
